Chroniques génomiques - Les débuts de CRISPR en thérapie génique

Abstract

Two clinical trials using CRISPR technology to engineer the T cells of cancer patients by inactivating the gene for immune checkpoint molecule PD-1 are (almost) underway, one in the USA and the other in China. The less sophisticated Chinese trial seems slated to begin first, in part because of very speedy approval ; it may however trigger autoimmune reactions that could be very serious.